Boston, Massachusetts, March 26, 2025 – Dewpoint Therapeutics Inc. – the leading biotechnology company in transforming condensate biology into medicine, […]

Boston, Massachusetts, January 29, 2025 – Dewpoint Therapeutics Inc. – the leading biotechnology company in transforming condensate biology into medicine, […]

Supporting Dewpoint’s novel condensate modulating approach to drug previously ‘undruggable’ therapeutic targets, guided by ConcertAI’s Clinico-Genomic Solutions  Boston, MA and […]

BOSTON, Massachusetts, December 4, 2024 – Dewpoint Therapeutics Inc., the leading biotechnology company that develops therapeutics by targeting biomolecular condensates, announced today […]

BOSTON, Massachusetts, October 28, 2024 – Dewpoint Therapeutics Inc., the leading biotechnology company that develops therapeutics by targeting biomolecular condensates, announced today the […]

Berlin, Germany and Boston, Mass., USA, October 24, 2024 – Bayer has entered into an exclusive licensing agreement with Dewpoint […]

BOSTON, Massachusetts, August 26, 2024 – Dewpoint Therapeutics Inc., the leading biotechnology company that develops therapeutics by targeting biomolecular condensates, announced today that […]

BOSTON, Massachusetts, January 11, 2024 – Dewpoint Therapeutics Inc., a biotechnology company that translates the novel science of condensates into breakthrough therapeutics, today […]

BOSTON, Massachusetts, January 7, 2024 – Dewpoint Therapeutics Inc., a biotechnology company that translates the novel science of condensates into breakthrough therapeutics, today […]

HAMBURG, Germany and BOSTON, Nov. 7, 2023 — Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and […]